MORTIMER IAN
Director · Officer · XENE
As of 2026-09-27, MORTIMER IAN has 53 Form 4 transactions on record across 1 company — 39 in the trailing 12 months.
Everything this person has disclosed to the SEC on Form 4 — across every company they file for — reconstructed from the public record. A filing history, not a tip sheet.
Pattern in the record: open-market sales filed in January in multiple years since 2025 — a recurring calendar cadence, more consistent with scheduled activity than a one-off decision.
Reconstructed holdings
- Direct $736K
- Indirect $0
| XENE | direct | 19,923 sh | $736K |
Reconstructed from this person's own Form 4 filings — the total each filing reported owning afterward, priced at the close on the as-of date shown. A filed position can lag the real one.
Direct and indirect holdings (e.g. through a trust or fund) are tagged separately, as filed.
Trades by company
Filing ledger
| Date | Company | Action | Shares @ price | Value | Ownership Δ | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-03-13 | XENE | Sale | 7,308 @ $55.23 | $404K | −26.8% of holding | 19,923 | Form 4 |
| 2026-03-10 | XENE | Sale | 11,269 @ $60.11 | $677K | −43.3% of holding | 14,731 | Form 4 |
| 2026-03-09 | XENE | Sale | 65,000 @ $62.06 | $4.0M | −91.5% of holding | 6,000 | Form 4 |
| 2026-03-09 | XENE | Sale | 61,652 @ $60.08 | $3.7M | −91.1% of holding | 6,000 | Form 4 |
| 2026-03-09 | XENE | Sale | 43,348 @ $59.26 | $2.6M | −37.4% of holding | 72,652 | Form 4 |
| 2026-03-09 | XENE | Sale | 31,694 @ $59.88 | $1.9M | −53.5% of holding | 27,515 | Form 4 |
| 2026-03-09 | XENE | Sale | 21,515 @ $60.49 | $1.3M | −78.2% of holding | 6,000 | Form 4 |
| 2026-03-09 | XENE | Sale | 21,791 @ $58.81 | $1.3M | −26.9% of holding | 59,209 | Form 4 |
| 2026-03-09 | XENE | Sale | 12,479 @ $59.50 | $743K | −40.3% of holding | 18,521 | Form 4 |
| 2026-03-09 | XENE | Sale | 10,072 @ $60.47 | $609K | −54.4% of holding | 8,449 | Form 4 |
| 2026-03-09 | XENE | Sale | 2,449 @ $61.26 | $150K | −29.0% of holding | 6,000 | Form 4 |
| 2026-01-02 | XENE | Sale | 37,938 @ $44.40 | $1.7M | −82.5% of holding | 8,062 | Form 4 |
| 2026-01-02 | XENE | Sale | 2,062 @ $44.93 | $93K | −25.6% of holding | 6,000 | Form 4 |
| 2025-12-08 | XENE | Sale | 8,820 @ $45.59 | $402K | −52.4% of holding | 8,010 | Form 4 |
| 2025-12-08 | XENE | Sale | 2,010 @ $46.32 | $93K | −25.1% of holding | 6,000 | Form 4 |
| 2025-12-05 | XENE | Sale | 14,375 @ $45.03 | $647K | −46.1% of holding | 16,830 | Form 4 |
| 2025-11-28 | XENE | Sale | 97 @ $45.01 | $4K | −0.3% of holding | 31,205 | Form 4 |
| 2025-10-01 | XENE | Sale | 25,000 @ $40.16 | $1.0M | −44.4% of holding | 31,302 | Form 4 |
| 2025-01-27 | XENE | Sale | 15,166 @ $40.46 | $614K | −32.6% of holding | 31,302 | Form 4 |
| 2025-01-27 | XENE | Sale | 1,149 @ $41.07 | $47K | −3.5% of holding | 31,302 | Form 4 |
| 2025-01-24 | XENE | Sale | 22,468 @ $40.20 | $903K | −41.8% of holding | 31,302 | Form 4 |
| 2025-01-23 | XENE | Sale | 16,217 @ $40.08 | $650K | −34.1% of holding | 31,302 | Form 4 |
31 award / exercise / gift records — not counted as purchases
| Date | Company | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|
| 2026-03-12 | XENE | Option exercise | 12,500 | 37,500 | Form 4 |
| 2026-03-12 | XENE | Option exercise | 12,500 | 27,231 | Form 4 |
| 2026-03-12 | XENE | Option exercise | 12,500 | 27,231 | Form 4 |
| 2026-03-09 | XENE | Option exercise | 75,000 | 81,000 | Form 4 |
| 2026-03-09 | XENE | Option exercise | 65,000 | 71,000 | Form 4 |
| 2026-03-09 | XENE | Option exercise | 105,000 | 111,000 | Form 4 |
| 2026-03-09 | XENE | Option exercise | 25,000 | 31,000 | Form 4 |
| 2026-03-09 | XENE | Award / grant | 20,000 | 20,000 | Form 4 |
| 2026-03-09 | XENE | Option exercise | 75,000 | 0 | Form 4 |
| 2026-03-09 | XENE | Option exercise | 105,000 | 0 | Form 4 |
| 2026-03-09 | XENE | Option exercise | 65,000 | 0 | Form 4 |
| 2026-03-09 | XENE | Option exercise | 25,000 | 0 | Form 4 |
| 2026-03-09 | XENE | Option exercise | 20,000 | 0 | Form 4 |
| 2026-03-09 | XENE | Option exercise | 20,000 | 26,000 | Form 4 |
| 2026-03-09 | XENE | Option exercise | 20,000 | 26,000 | Form 4 |
| 2026-01-09 | XENE | Award / grant | 65,000 | 65,000 | Form 4 |
| 2026-01-09 | XENE | Award / grant | 350,000 | 350,000 | Form 4 |
| 2026-01-02 | XENE | Option exercise | 40,000 | 46,000 | Form 4 |
| 2026-01-02 | XENE | Option exercise | 40,000 | 0 | Form 4 |
| 2025-10-01 | XENE | Option exercise | 25,000 | 56,302 | Form 4 |
| 2025-10-01 | XENE | Option exercise | 25,000 | 0 | Form 4 |
| 2025-03-12 | XENE | Award / grant | 275,000 | 275,000 | Form 4 |
| 2025-03-12 | XENE | Award / grant | 50,000 | 50,000 | Form 4 |
| 2025-01-27 | XENE | Option exercise | 15,166 | 46,468 | Form 4 |
| 2025-01-27 | XENE | Option exercise | 1,149 | 32,451 | Form 4 |
| 2025-01-27 | XENE | Option exercise | 16,315 | 0 | Form 4 |
| 2025-01-24 | XENE | Option exercise | 22,468 | 53,770 | Form 4 |
| 2025-01-24 | XENE | Option exercise | 22,468 | 16,315 | Form 4 |
| 2025-01-23 | XENE | Option exercise | 16,217 | 47,519 | Form 4 |
| 2025-01-23 | XENE | Option exercise | 16,217 | 38,783 | Form 4 |
| 2024-03-11 | XENE | Award / grant | 250,000 | 250,000 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.